Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06129916
Other study ID # RES-00617
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 1, 2024
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source PATH
Contact Kimberly Green, MA, PhD
Phone +1(202)-515-0626
Email kgreen@path.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of the proposed study is to generate evidence on the acceptability, feasibility, effectiveness, and cost-effectiveness of introducing long-acting depot buprenorphine (LADB) as an additional option for the treatment of opioid dependence in low- and middle-income countries (LMIC) among people who inject drugs (PWID) with opioid dependence. The study results will be used to inform global and local policies and guidelines to introduce LADB as a treatment option and to advocate for access to a sustainable supply of LADB in LMIC.


Description:

Despite the proven effectiveness of opioid agonist maintenance treatment (OAMT), its coverage and use remain low globally and, particularly, in low- and middle-income countries (LMIC), in part due to challenges related to limited choice of OAMT medication and dosing options. The long-acting depot buprenorphine (LADB) formulation of OAMT, with either weekly or monthly administration, could provide a more discreet, convenient, and less stigmatizing form of treatment and the potential to improve client retention in care, as well as economic stability. It therefore may address unmet need among individuals who could benefit from OAMT and are not already taking it or who would prefer a long-acting option over current OAMT options. Studies have demonstrated the effectiveness and acceptability of LADB among those with opioid dependence in high-income settings. However, there are no known such studies conducted in LMIC. The aim of the study is to determine the acceptability, feasibility, effectiveness, public health impact, and cost-effectiveness of introducing LADB in a range of LMIC. The study will collect data from participants with opioid use disorder, service providers, and health policymakers/decision-makers across seven diverse LMIC: Egypt, India, Kyrgyzstan, South Africa, Tanzania, Ukraine, and Vietnam. This is a multicenter, mixed-method study designed with community engagement and co-production. The study consists of four interlinked modules: Module 1 (feasibility) includes a process evaluation to monitor implementation and assess barriers, drawing on program data and interviews with service providers and other key stakeholders; Module 2 (effectiveness) involves a prospective cohort choice study among people with opioid dependence, initiating LADB and following up over 48 weeks; Module 3 (values and preferences, plus acceptability) includes key informant interviews and focus group discussions with people with opioid dependence to understand overall acceptability, values, preferences, experiences, and concerns relating to LADB; Module 4 (public health impact and cost-effectiveness) involves modeling based on collected data to estimate impact and cost-effectiveness of LADB in LMIC settings.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1050
Est. completion date December 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Are 18 years old or older. - Are verified (by certified clinician) opioid dependents according to the International Classification of Diseases 11th Revision. - Are not pregnant (verified by screening). - Are eligible to receive OAMT at a participating site. - Consent to attend the clinic and adhere to clinical protocols - Have the capacity to consent to participating in research. - Provide written informed consent. Exclusion Criteria: - Have a history or presence of an allergic or adverse response (including rash or anaphylaxis) to BUP or the AtrigelĀ® delivery system (a registered trademark of Tolmar Therapeutics Inc.) if Sublocade is chosen. - Have any contraindication to BUP or methadone. - Show signs of clinically significant medical conditions which would compromise compliance with the protocol and/or client safety in line with clinical guidelines for the administration of injectable BUP for OAMT. - Are currently taking oral or depot naltrexone therapy or are enrolled in any form of naltrexone therapy within 30 or 90 days prior to study screening, respectively. - Are in thepost partum period (defined as 6 weeks) or confirmed as pregnant. - Have an inability or unwillingness to provide informed consent or abide by the requirements of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
long-acting depot buprenorphine (LADB)
The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.

Locations

Country Name City State
n/a

Sponsors (13)

Lead Sponsor Collaborator
PATH Alliance for Public Health, Burnet Institute, Coact Technical Support Limited, Frontline AIDS, International Network of People who Use Drugs, London School of Hygiene and Tropical Medicine, Médecins du Monde, Monash University, Population Services International, UNITAID, University of Bristol, World Health Organization

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Satisfaction Questionnaire for Medication 1.4 assessed through patient reported outcomes on effectiveness, side-effects, convenience and global satisfaction in relation to the medication The primary measure for treatment satisfaction will be collected through the Treatment Satisfaction Questionnaire for Medication 1.4 at 48 weeks. This is a generic measure of treatment satisfaction with medication. It has 14 questions divided into subscales (effectiveness; side effects, convenience and global satisfaction). Response are on a Likert-scale of 5 or 7 points except for 1 yes/no question on the presence of side effects. The scores are calculated for each of the subscales, which range from 0 to100 with higher scores indicating higher patient satisfaction with medication. 48 weeks
Primary Retention in Care The primary measure for retention in care will be estimated as the proportion of people on LADB at 48 weeks 48 weeks
Primary Nonmedical opioid use Assess degree of non-medical opioid use in the last month measured at week 48, in terms of number of days that non-medical opioids were not used in the last 4 weeks. 48 weeks
Secondary % of participants who have received testing for HIV and Hepatitis C (HCV) at 48 weeks, frequency of testing, % testing positive for antibodies to HIV or HCV and % linked to treatment and % retained into treatment Retention into HIV treatment will be measured through self-report using a predefined threshold of adherence (80 to 100%) in consultation with sites as well as through recoding return visits for medication refills. Retention into HCV treatment will be measured as the proportion of those completing treatment and who have sustained virologic response 12 weeks after treatment. These data will be extracted from clinical records at programme sites. 48 weeks
Secondary % of participants with self reported symptoms of depression at 48 weeks. Measured through the self-completion scale (PHQ-9 [9-question Patient Health Questionnaire] with scale from 0-3, lower score indicating better mental health 48 weeks
Secondary % of participants with self-reported symptoms of anxiety at 48 weeks. Measured through the self-completion scale GAD-7 [Generalized Anxiety Disorder 7) with scale from 0-3, lower score indicating better mental health 48 weeks
Secondary % of participants reporting recent thoughts of or attempts at suicide at 48 weeks. This will be taken from other studies among people who inject drugs with "suicidality" specified as recent (within last 4 weeks) thoughts of and attempts at suicide. 48 weeks
Secondary Patient-reported outcomes using the EuroQol measures of health status Patient-reported outcomes (PROMs) assessing health-related quality of life will include the EQ5D-5L, which measures the five dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (range 1-5, lower score indicates better health) 48 weeks
Secondary Patient-reported outcomes using the EuroQol visual analogue scale (EQVAS) Patient-reported outcomes (PROMs) assessing health-related quality of life using a visual analogue scale EQVAS (range 0-100, higher score indicates better health). 48 weeks
Secondary % of participants reporting a non-fatal overdose in the last 6 months This will be defined as losing consciousness due to a drug-related overdose (opioids or ATS) in the last 6 months. 48 weeks
Secondary % of participants reporting risky levels of alcohol use (range 0-12, higher score indicates higher risk alcohol use). Self-reported alcohol use will be measured using the Alcohol Use Disorders Identification Test (AUDIT) 48 weeks
Secondary % of participants reporting experience of Stigma and discrimination is measured through the substance use stigma mechanism scale (SU-SMS) (range 1-5, higher scores denote greater stigma and discrimination) Stigma and discrimination will be measured using the substance use stigma mechanism scale that measures enacted and internalized stigma from family and health care workers. 48 weeks
Secondary % of participants reporting being arrested by the police in the last 6 months measured at 48 weeks. This is a self reported measure: "In the last 6 months, have you been arrested or detained or charged by police in (XX location) for any reason?" 48 weeks
Secondary % of participants who have been in prison in the last 6 months measured at 48 weeks This is a self-reported measure: "In the last 6 months, have you spent time in prison, jail or a young offenders institute?" 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Terminated NCT00768482 - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Phase 3
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Phase 3
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1